Back to search results

A Study of Ritlecitinib for Moderate Alopecia Areata

This study is looking into the safety and effects of ritlecitinib for people with moderate alopecia areata (patchy hair loss). You may be able to join if you are 12 years or older (with local approval) and have had patchy hair loss for 6 months to 10 years, without other hair loss conditions. Participants will receive either ritlecitinib (50 mg or 100 mg capsules) or a placebo (an inactive capsule that looks the same). The main goal is to see if ritlecitinib 50 mg helps improve hair regrowth by Week 24 compared to placebo. The study aims to enroll 336 people, but its current status is unclear.

Study design
This is an interventional study where participants will be randomly assigned to receive ritlecitinib (50 mg or 100 mg) or a placebo. There's a 2 in 3 chance of receiving ritlecitinib 50 mg and a 1 in 3 chance of receiving placebo, and you won't know which you are getting. The study plans to enroll 336 participants.
What's involved
Not specified in the trial record.
Compensation
Not stated in the trial record.
Follow-up
The primary outcome is measured at Week 24, which is when the main comparison between ritlecitinib and placebo will be assessed.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT07733765

A Study in Young People and Adults to Learn About the Medicine Ritlecitinib for Treatment of Patchy Hair Loss, Known by the Medical Term as Moderate Alopecia Areata

Not Yet Recruiting
PHASE3Ages 12+InterventionalTreatment
Pfizer
~336 participants
Updated 2026-07-29 on ClinicalTrials.gov
What's tested:Ritlecitinib 100 mgRitlecitinib 50 mgPlacebo

At a glance

Recruiting sites
0 of 4 listed sites are recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Difference in the proportion of Severity of Alopecia Tool (SALT) 0 responders at Week 24 between ritlecitinib 50 mg QD versus placebo
Measured over Week 24

Conditions

Alopecia Areata

Explore related trials

Alopecia

Where it's being run

4 sites across 3 states
Texas2
Indiana1
Iowa1

Study leadership

  • Pfizer CT.gov Call Center · STUDY_DIRECTOR · Pfizer

Who to contact

Pfizer CT.gov Call Center
[email protected]
1-800-718-1021
Email the study team

Opens a ready-to-send draft in your own email app — review before sending.

Do you actually qualify for this trial?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

18 years or older (or the minimum age of consent in accordance with local regulations) at screening. Adolescents (12 to \<18 years of age at screening) are also eligible for this study, but only if permitted by the local IRB/EC and local regulatory health authority (if applicable). Where these approvals have not been granted, only participants 18 years of age and older at screening will be enrolled
Have a clinical diagnosis of AA with no other etiology of hair loss.
Have \>20% to \<50% hair loss of the scalp, as measured by SALT.
Current AA episode of hair loss ≥6 months and ≤10 years (Current episode is defined as the continuous period of AA-related scalp hair loss since the last time the subject had no visible scalp patches).

Exclusion

Other types of alopecia (including, but not limited to, traction and scarring alopecia, telogen effluvium). Participants with androgenetic alopecia will be excluded.
Other scalp disease that may impact AA assessment (eg, scalp psoriasis, dermatitis, etc.).
Active systemic diseases that may cause hair loss (eg, lupus erythematosus, thyroiditis, systemic sclerosis, lichen planus, etc).

What this trial measures

  • Difference in the proportion of Severity of Alopecia Tool (SALT) 0 responders at Week 24 between ritlecitinib 50 mg QD versus placeboWeek 24